

Tumor Necrosis Factor (TNF) Inhibitors

A review of structure, function, and mechanism of action

By Joseph Flood, MD, FACR

President, Musculoskeletal Medical Specialists Inc.;
Clinical faculty member, The Ohio State University
College of Medicine and Public Health, Columbus

Supplement to

M A N A G E D
Care

Volume 17, No. 5
Supplement 4
May 2008

This publication is supported by Amgen

Tumor Necrosis Factor (TNF) Inhibitors

A review of structure, function, and mechanism of action

The use of biologic response modifiers (BRMs) to treat chronic inflammatory conditions is of great interest to managed care organizations (MCOs). Growing utilization, an increasing number of new market entrants, and the expansion of therapeutic indications for existing products are forcing MCOs to focus on BRMs as a high priority for controlling drug spending (Cohen 2006). However, even for the BRMs that share a primary biologic target (Table 1), the lack of other commonalities typical of a well-defined pharmacologic class limits the utility of a preferred formulary (Flood 2007). For instance, tumor necrosis factor (TNF) inhibitors cannot be considered interchangeable in accordance with the position statement issued by the Academy of Managed Care Pharmacy (AMCP 2003). Specifically, there is no supporting evidence to indicate that TNF inhibitors are therapeutically equivalent; rather, they have considerable structural, binding, and functional differences (vanVollenhoven 2007, Flood 2007). Switching to another TNF inhibitor has been shown to be of benefit to some patients, as their response rates and levels of tolerance may vary (vanVollenhoven 2007). This article examines differences among the TNF inhibitors in terms of structure, binding profile, and activity at the point of impact. Understanding these differences is critical in the development of effective benefit design and coverage policies.

Structure and binding profile

The key difference among the TNF inhibitors lies in their molecular structures. Etanercept is a human soluble receptor fusion protein (Enbrel 2008); adalimumab and

infliximab are monoclonal antibodies (mAbs). Although adalimumab is fully human, infliximab contains both human and murine regions (Humira 2008, Remicade 2007).

TNF- α is a binding target for all TNF inhibitors. In addition, etanercept binds to TNF- β , also known as lymphotoxin alpha (LT- α) (Enbrel 2008, Furst 2006). In the evaluation of the binding and functional differences among the TNF inhibitors, it is important to understand the biologic activity of their binding targets.

TNF- α is well recognized for its central role in mediating chronic inflammatory diseases (Furst 2006). In fact, elevated levels of TNF- α have been detected in patients with rheumatoid arthritis (RA), psoriatic arthritis, psoriasis, and Crohn's disease (Robak 1998, Mussi 1997, Komatsu 2001). The biologic role of LT- α in the immunopathogenesis of inflammatory conditions has not yet been established (Furst 2006). Sufficient levels of both these mediators are critical for sustaining normal immune responses (Ehlers 2005, Wallis 2005, Furst 2006). TNF- α activates and recruits cells involved in the antimicrobial protective processes, including formation and maintenance of granulomas, whereas LT- α regulates local organization of the granulomatous response. Furthermore, animal model studies have demonstrated that deficiency in TNF- α or LT- α results in increased susceptibility to granulomatous infections, such as tuberculosis (Flynn 1995, Bean 1999, Turner 2001, Roach 2001). It is interesting to note that granulomas are not unique to infectious processes; they also can be found in chronic inflammatory conditions such as Crohn's disease, where

TABLE 1
Biologic response modifiers approved for the treatment of chronic inflammatory conditions

Biologic target	Product	Description	Route of administration
TNF	Adalimumab	Human monoclonal antibody	Subcutaneous
	Etanercept	Human soluble receptor	Subcutaneous
	Infliximab	Chimeric monoclonal antibody	Intravenous
T-cell	Abatacept	Human soluble fusion protein	Intravenous
	Alefacept	Human dimeric fusion protein	Intravenous
	Efalizumab	Humanized monoclonal antibody	Subcutaneous
B-cell	Rituximab	Chimeric monoclonal antibody	Intravenous
IL-1	Anakinra	Human IL-1 receptor antagonist	Subcutaneous

IL=interleukin, TNF=tumor necrosis factor.

SOURCES: MANUFACTURERS' PRESCRIBING INFORMATION

TABLE 2**Functional attributes of tumor necrosis factor (TNF) inhibitors**

Attributes	Human soluble receptor (etanercept)	Monoclonal antibodies (infliximab, adalimumab)
Binding targets	<ul style="list-style-type: none"> • TNF-α • TNF-β (LT-α) 	<ul style="list-style-type: none"> • TNF-α
TNF- α binding selectivity	<ul style="list-style-type: none"> • Bioactive/trimer TNF-α 	<ul style="list-style-type: none"> • Bioactive/trimer TNF-α • Inactive/monomer TNF-α*
Complex formation with TNF- α	<ul style="list-style-type: none"> • No large protein complexes 	<ul style="list-style-type: none"> • Large protein complexes
TNF- α binding stability	<ul style="list-style-type: none"> • Unstable with rapid dissociation 	<ul style="list-style-type: none"> • Stable with slow dissociation
Induction of cytotoxic responses	<ul style="list-style-type: none"> • Apoptosis: <ul style="list-style-type: none"> ◦ Monocytes in RA 	<ul style="list-style-type: none"> • Apoptosis: <ul style="list-style-type: none"> ◦ Monocytes in RA and CD* ◦ T-cells in CD • Lysis
Impact on INF- γ activity	<ul style="list-style-type: none"> • Lesser effect 	<ul style="list-style-type: none"> • Reduction in TB-responsive T-cells • Suppressed production

* Data available only for infliximab

CD=Crohn's disease, INF= interferon, LT=lymphotoxin, RA=rheumatoid arthritis, TB=tuberculosis.

SOURCES: MANUFACTURERS' PRESCRIBING INFORMATION, SCALLON 2002, KOHNO 2007, SANTORA 2001, LUGERING 2006, FURST 2006, SALIU 2006

TNF- α has been implicated in the inflammatory cycle (Heresbach 2005).

Owing to their structural differences, TNF inhibitors display fundamentally diverse TNF- α binding characteristics. First, etanercept targets only the bioactive form of TNF- α , which is a trimer (Scallon 2002). In contrast, infliximab has been shown to bind not only to the trimeric form of TNF- α , but also to its inactive monomeric precursors (Scallon 2002). It is suspected that adalimumab also binds to both forms of TNF- α . Binding to the TNF monomers may interfere with the formation of the bioactive trimeric TNF (Scallon 2002). Second, the mAbs have been shown to form large complexes with the TNF- α molecules, which may lead to antibody- and complement-dependent cellular cytotoxicity (Kohno 2007). Third, the TNF dissociates from etanercept at a significantly faster rate than that seen with the mAbs (Scallon 2002, Santora 2001). When the TNF dissociates from etanercept, it remains bioactive (Scallon 2002). Thus, it has been suggested that in comparison with etanercept, the mAbs have a greater potential for neutralization of the TNF. As mentioned previously, sufficient levels of TNF- α are needed to sustain normal immune response.

Activity at the points of impact

A comparison of the binding profiles of the TNF inhibitors helps to highlight the potentially important functional differences among these agents. First, the potential to induce cellular apoptosis may vary (Lugering 2006), and

the role of cellular mediators and the mechanisms of action underlying their therapeutic effects may vary with each disease state. For instance, unlike etanercept, the anti-TNF mAbs have demonstrated induction of apoptosis in monocytes and lymphocytes extracted from patients with Crohn's disease (Van den Brande 2003, Shen 2005). However, in a study involving cells extracted from the joints of patients with RA (Catrina 2005), etanercept and infliximab showed similar effects — both agents induced apoptosis in monocytes, but not lymphocytes.

TNF inhibitors also may have different propensities for lysing cells that express TNF on their membranes (Strand 2007, Furst 2006). It is believed that when bound to the transmembrane TNF, the mAbs can lead to cellular lysis. In contrast, etanercept has not shown to induce lysis *in vitro* in the presence or absence of complement. Although the clinical significance of this difference is unknown, lysis of cells with transmembrane TNF may be associated with a greater susceptibility to granulomatous infections (Furst 2006). It should be noted that TNF-expressing cells include monocytes, macrophages, and lymphocytes, all of which play a critical role in the formation of granulomas (Wallis 2005).

Conclusion

In an effort to control utilization of TNF inhibitors, MCOs may be compelled to apply traditional category management techniques, including the selection of a preferred agent. Given the significant differences among

